• Kevin J. Woolf
  • Robert C. Block


Dyslipidemia is a common disorder of abnormal metabolism or levels of one or more of various triglyceride or cholesterol molecules. Based on the most recent guidelines established by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III, approximately 23% of the United States population requires treatment for a cholesterol abnormality with either lifestyle modification or administration of medications [1]. Hypercholesterolemia is a well established risk factor for the development of coronary artery disease (CAD) [2], and is a strong marker for mortality in patients with CAD [3]. There is an ever increasing body of evidence that suggests aggressive treatment of dyslipidemia in an at-risk population (primary prevention) as well as in patients with established CAD (secondary prevention) is essential in the prevention of CAD and its complications.


High Density Lipoprotein National Cholesterol Education Program Coronary Artery Disease Risk High Density Lipoprotein Level Intermediate Density Lipoprotein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.Google Scholar
  2. 2.
    The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA. 1976;235:825–7.Google Scholar
  3. 3.
    Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Rifkind B, Levy RI. Hyperlipidemia: diagnosis and therapy. New York: Grune & Stratton; 1977.Google Scholar
  5. 5.
    Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340:115–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114:2710–38.PubMedCrossRefGoogle Scholar
  7. 7.
    Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation. 1965;31:321–7.PubMedGoogle Scholar
  8. 8.
    Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971;75:471–2.PubMedGoogle Scholar
  9. 9.
    Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non–HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B.PubMedCrossRefGoogle Scholar
  11. 11.
    Amarenco P, Lavallee P, Touboul PJ. Statins and stroke prevention. Cerebrovasc Dis. 2004;17 Suppl 1:81–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Zandi-Nejad K, Brenner BM. Strategies to retard the progression of chronic kidney disease. Med Clin North Am. 2005;89:489–509.PubMedCrossRefGoogle Scholar
  13. 13.
    Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998;339:12–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Vaughan CJ, Gotto Jr AM. Update on statins: 2003. Circulation. 2004;110:886–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.PubMedCrossRefGoogle Scholar
  17. 17.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 1998;32:665–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.Google Scholar
  22. 22.
    Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.Google Scholar
  23. 23.
    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.Google Scholar
  24. 24.
    Pfeffer MA, Sacks FM, Moye LA, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol. 1995;76:98C–106C.PubMedCrossRefGoogle Scholar
  25. 25.
    Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.PubMedCrossRefGoogle Scholar
  26. 26.
    LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.PubMedCrossRefGoogle Scholar
  27. 27.
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.PubMedCrossRefGoogle Scholar
  28. 28.
    Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83:687–700.PubMedCrossRefGoogle Scholar
  29. 29.
    Paoletti R, Holmes WL. Drugs affecting lipid metabolism. Berlin/New York: Springer; 1987.Google Scholar
  30. 30.
    Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.PubMedCrossRefGoogle Scholar
  32. 32.
    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–64.Google Scholar
  33. 33.
    Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80:587–95.PubMedCrossRefGoogle Scholar
  34. 34.
    Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–43.PubMedCrossRefGoogle Scholar
  35. 35.
    Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.PubMedCrossRefGoogle Scholar
  38. 38.
    Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97:946–52.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.Division of CardiologyUniversity of Rochester Medical CenterRochesterUSA
  2. 2.Department of Community and Preventive MedicineThe University of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations